Publicacións (31) Publicacións de María Inés Gómez Otero

2024

  1. Delay in cardiology consultation after primary care physician referrals in heart failure: Clinical implications

    ESC Heart Failure

  2. Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis

    Medicina Clinica, Vol. 162, Núm. 7, pp. e1-e7

  3. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

    Clinical Research in Cardiology, Vol. 113, Núm. 8, pp. 1171-1182

  4. Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 634-644

2023

  1. Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 2875-2881

  2. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1193-1204

2022

  1. Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy

    Mayo Clinic Proceedings, Vol. 97, Núm. 2, pp. 261-273

  2. Cardiac amyloidosis: Description of a series of 143 cases

    Medicina Clinica, Vol. 159, Núm. 5, pp. 207-213

  3. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life

    ESC Heart Failure, Vol. 9, Núm. 5, pp. 3071-3078

  4. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

    Journal of Clinical Medicine, Vol. 11, Núm. 5

  5. Syncope in patients with transthyretin amyloid cardiomyopathy: clinical features and outcomes

    Postgraduate Medicine, Vol. 134, Núm. 4, pp. 420-428

2021

  1. A New Biomarker Tool for Risk Stratification in “de novo” Acute Heart Failure (OROME)

    Frontiers in Physiology, Vol. 12

  2. Sex and Heart Failure Treatment Prescription and Adherence

    Frontiers in Cardiovascular Medicine, Vol. 8

2020

  1. Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 73, Núm. 7, pp. 561-568

  2. Endocardial autonomic denervation in a patient with neurally mediated syncope and severe cardioinhibitory response

    Revista Espanola de Cardiologia, Vol. 73, Núm. 11, pp. 959-961

  3. Neurohormonal blockade in heart failure patients with preserved ejection fraction: is there any evidence?

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 128-130

2019

  1. Leadless Pacemaker Implantation in a Transplanted Heart

    Revista Espanola de Cardiologia, Vol. 72, Núm. 3, pp. 270-272

  2. Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure

    Journal of Cardiovascular Translational Research, Vol. 12, Núm. 3, pp. 231-239

2018

  1. Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings

    Revista Espanola de Cardiologia, Vol. 71, Núm. 10, pp. 820-828

  2. Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: Impact in de novo heart failure patients

    International Journal of Medical Sciences, Vol. 15, Núm. 5, pp. 417-424